| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2120509 | Drug Resistance Updates | 2008 | 9 Pages |
Abstract
Activation of Notch signaling has been implicated in pathogenesis of various hematologic tumors including leukemias, lymphomas, and multiple myeloma. Pre-clinical studies have suggested that inhibition of Notch could be an attractive new approach to treatment of hematologic malignancies. This review discusses most recent findings in the field and potential role of Notch signaling as a therapeutic target focusing on the effects of γ-secretase inhibitors.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Yulia Nefedova, Dmitry Gabrilovich,